The Cancer Molecular Diagnostics Laboratory (CMDL) was established in 2015 to develop new technologies in relation to detailed molecular genetic profiling using next generation sequencing and for sequencing modified bases in DNA. The CMDL is a shared resource that provides clinically actionable genomic results for patients enrolled on clinical trials and clinical studies led by researchers across the Centre. CMDL experimental workflows include processing and analysing fresh frozen and formalin-fixed paraffin embedded tissue (FFPE) as well as circulating tumour DNA and Germ line DNA from blood samples and processed blood products; these workflows will then be translated into standardised protocols for routine analysis.